Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study seeks to identify who benefits from Last-Resort blood pressure drugs

NCT ID NCT07579260

Knowledge-focused Sponsor: Vivek Bhalla Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This study will follow 100 adults whose high blood pressure remains high despite taking at least two medications. Over three months, researchers will track changes in blood pressure and other health markers to find patterns that could help identify which patients might respond best to fourth-line treatments, including the FDA-approved drug aprocitentan. No new treatments are given; the goal is to gather real-world data to guide future care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify which patients with resistant hypertension are most likely to benefit from newer medications like aprocitentan.
What could go wrong
This is an observational study, not a treatment trial. It will not test whether any drug works, and results may not apply to all patients with hypertension.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will include 100 patients with inadequately controlled blood pressure despite the use of two therapies.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed and dated informed consent form * Ability to answer survey questions and to report blood pressure reading monthly * Male and female participants; 18 years or older * Treated with at least 2 antihypertensive therapies of different pharmacological classes for at least 4 weeks before the screening visit * Mean Sitting Systolic Blood Pressure (SiSBP) greater or equal to 130 mmHg Exclusion Criteria: * Confirmed severe hypertension (grade 3) defined as SiSBP greater than or equal to 180 mmHg and/or Sitting Diastolic Blood Pressure (SiDBP) greater than or equal to 110 mmHg * Clinically significant unstable cardiac disease at screening or in the past in the opinion of the investigator * Heart failure NYHA functional class III and IV or NT-proBNP \> 500 pg/mL * Severe renal insufficiency or eGFR \< 15 mL/min/1.73m2 * Moderate to severe hepatic impairment (Child-Pugh B and C) or elevated aminotransferase (\> 3 x ULN)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blood pressure, high are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertensive disorder resistant hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blood pressure, high Hypertension Hypertension (HTN)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Duke University Hospital

    Durham, North Carolina, 27710, United States

  • Stanford University Hypertension Center

    Palo Alto, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.